This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Participants with Adverse Events
Timeframe: 52 weeks
Percentage of Participants with Clinically Significant Laboratory Values (clinical chemistry, complete blood count, urinalysis) as assessed by the Investigator
Timeframe: 52 weeks
Percentage of Participants with Clinically Significant ECGs as assessed by the Investigator
Timeframe: 52 weeks
Percentage of Participants with Clinically Significant vital sign measurements as assessed by the Investigator
Timeframe: 52 weeks
Percentage of Participants with any new Physical examination abnormality or worsening of change from baseline
Timeframe: 52 weeks
Percentage of Participants with any new neurological abnormality post baseline or worsening of change from baseline
Timeframe: 52 weeks